ArticleJHEP reports : innovation in hepatology2026
Liver fibrosis is associated with clinical and economic burden of cardiovascular disease in MASH.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Using artificial intelligence to identify characteristics associated with clinical and economic outcomes in MASH (FOCUS-MASH).Therapeutic advances in gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Aims: The clinical and economic burden of cardiovascular (CV) disease (CVD) in patients with metabolic dysfunction-associated steatohepatitis (MASH) is incompletely understood. The unCoVer-MASH cohort study aimed to assess the association of CVD-related burden with fibrosis (Fibrosis-4 index [FIB-4]) in patients with MASH in a real-world US database. Methods: Adult patients with an ICD code for non-alcoholic steatohepatitis (NASH; October 2015-June 2022) were included if they had ≥1 FIB-4 measurement calculated from data obtained within 180 days before or 30 days after the NASH diagnosis (index date), ≥12 months of data prior to the index date (baseline period), and no diagnostic evidence of cirrhosis at baseline. FIB-4 categories were low (<1.30), intermediate (1.30-2.67), and high (>2.67). Risk of CV events was assessed during follow-up, and hazard ratios (HRs) were calculated using Cox proportional hazards models. CVD-related economic burden and resource utilization were also assessed. Results: Of 715 patients included at baseline,102 had high, 201 had intermediate, and 412 had low FIB-4 scores. The risk of any CV event was significantly greater in the high (HR 3.44; 95% CI 2.22-5.34; Conclusions: Patients with MASH and high baseline FIB-4 scores were at an increased risk of CV events and had higher CV-related healthcare costs and resource utilization. Impact and implications: Studies specifically evaluating the clinical and economic burden of CVD in patients with MASH, without diagnostic evidence of cirrhosis, are lacking. In the current study, the clinical and economic burden of CVD in such patients was associated with baseline liver fibrosis severity, as assessed using baseline FIB-4 score, indicating a higher CV burden among patients with higher fibrosis severity. These results are important for both clinicians and payers, as they illustrate that tackling the CV-related burden in MASH is likely to have an appreciable impact on both clinical and economic outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.